Regulation of hypoxia-inducible gene expression with antisense Inhibitory PAS domain protein
AssigneeAngioGenetics Sweden AB
InventorsYuichi Makino, Lorenz Poellinger
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition comprises the sequence of SEQ ID NO:s 3-5 or pharmaceutically equivalent sequences. Methods employing the pharmaceutical compositions include treatments to increase angiogenesis, to stimulate HIF-1α function, to treat hypoxia-related conditions, and to maintain normal cell functions under hypoxia.
Claims10
A pharmaceutical composition, comprising the sequence of SEQ ID NO:5 and at least one pharmaceutical carrier.
A pharmaceutical composition, comprising a sequence having 95% homology to the sequence of SEQ ID NO:5 and at least one pharmaceutical carrier.
A pharmaceutical composition, comprising a sequence having 90% homology to the sequence of SEQ ID NO:5 and at least one pharmaceutical carrier.
A pharmaceutical composition, comprising a sequence having 85% homology to the sequence of SEQ ID NO:5 and at least one pharmaceutical carrier.
A pharmaceutical composition, comprising a sequence having 80% homology to the sequence of SEQ ID NO:5 and at least one pharmaceutical carrier.
A pharmaceutical composition, comprising a sequence having 75% homology to the sequence of SEQ ID NO:5 and at least one pharmaceutical carrier.
A pharmaceutical composition, comprising a sequence having 70% homology to the sequence of SEQ ID NO:5 and at least one pharmaceutical carrier.
A plasmid comprising the sequence of SEQ ID NO:
- 5.
An isolated host cell expressing the protein encoded by SEQ ID NO:5.
Dependencies are inferred from the claim text.